AI-Powered Cancer Diagnostics
Fast, Accurate, and Personalised
Diagnexia and Artera are bringing AI multimodal risk stratification tools for localised prostate and breast cancer to the UK. Providing rapid, reliable insights to clinicians and patients.
Order Now%20(500%20x%20500%20px)%20(1).png)
Prostate Cancer
An AI precision medicine test for prostate cancer, which helps clinicians and patients come to a shared decision on an optimal personalised treatment plan.
By analysing images of the prostate biopsy tissue alongside clinical data, it provides a novel prognostic risk score which estimates the risk of metastasis and prostate cancer-specific mortality over 10 years. Uniquely, it also determines whether intermediate-risk patients would benefit from adding Short-Term Androgen Deprivation Therapy (ST-ADT) to radiation therapy.
For lower-risk patients, it provides insights into the patient’s suitability for active surveillance, and for high-risk patients it determines whether they would benefit from the addition of Abiraterone therapy.
ArteraAI is the only predictive tool for ST-ADT recommended in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for localized prostate cancer, backed by Level 1B evidence.
Breast Cancer
An AI precision medicine test for HR+/HER2- early stage invasive breast cancer, which helps clinicians and patients come to a shared decision on an optimal personalised treatment plan.
By analysing images of the breast resection tissue alongside clinical data, it produces a prognostic risk score which estimates the risk of metastasis over 5 and 10 years. For patients who are node negative and older than 50, the ArteraAI Risk group predicts whether the patient would benefit from chemotherapy.
The test does not consume tissue, and the algorithm takes under 2 hours to run - much faster than existing genomic tests.
A Partnership Transforming Cancer Diagnostics
Diagnexia’s expertise in digital pathology and AI-driven diagnostics
Artera’s cutting-edge AI technology and clinical validation
The first multimodal AI risk stratification tool recommended by NCCN in the USA
"This partnership highlights the transformative potential of AI in revolutionising personalised cancer care. As the first and only global digital pathology service, Diagnexia has been at the forefront of digital innovation from the start. We see this new wave of digital biomarkers as a pivotal advancement, and by combining our expertise with Artera’s innovative technology, we aim to transform digital diagnostics services in the UK and beyond.”
- Donal O’Shea, CEO, Diagnexia
Request More Information
Key Benefits for Clinicians & Patients
Enhanced Risk Stratification
Therapy Guidance & Empowered Decision making
Fast & Accurate
Results
Sitemap
HomeSpeedSpeedSpeedSpeedExpertiseExpertiseExpertiseExpertiseEaseEaseEaseEaseNews & ResourcesNews & ResourcesNews & ResourcesNews & ResourcesContactContactContactContactRequest ConsultFollow Us
